Back to Ideas

Women’s representation in clinical research
2026 Mar 3
Pharma and Biotech
As a women-led company, equitable representation of women in healthcare research is especially important to us. As we strive to focus equally on women’s and men’s perspectives in our patient experience work, we find it useful to look back and see how women’s representation in research has changed over time. To the surprise of no one, women have not always been adequately represented in clinical research for conditions that impact all patients regardless of biological sex.
We can go back to the 1970s, for example, when the U.S. FDA had a policy which recommended excluding certain women (those who are pregnant and/or of child-bearing potential) from phase 1 drug clinical research. Researchers often applied the recommendation broadly, resulting in exclusion of women across any phase of interventional drug research. After rising concerns and protests related to the lack of clinical data in women’s health, a new law took effect in 1994, which required National Institutes of Health funded clinical research to include women and minorities as participants (with some exceptions).
Since then, progress has been made, but there still exists a large gap in understanding women’s health. Beyond sexual and reproductive health differences, evidence shows that women experience certain health conditions more frequently or differently than men — like osteoporosis, depression, autoimmune diseases, heart attacks, etc.
Everyone should have the choice and ability to weigh the potential benefits and risks of treatment, which necessitates that there is funding, priority, and clinical outcomes data specific to the experiences of women!
We hope to see more efforts being made to close the gap.

To learn more about efforts in this space in the last few years, check out:

Our other ideas worth exploring

Improving accessibility

Improving accessibility

2026 May 1 |

A UX design lens helps us create digital materials that are as intuitive and accessible as possible. This can make a big difference, especially in advanced therapies for rare and complex diseases, where patients are often quite sick and faced with increasingly difficult treatment decisions.

read more
Clarifying clinical trial results

Clarifying clinical trial results

2026 Apr 29 |

For brands, communicating clinical trial results is usually paramount—the clinical efficacy data, balanced by the side effects observed, is the foundation of the product’s value proposition for patients. But clinical trial data is typically complex, and can be difficult for patients to understand.

read more
Redesigning Important Safety Information (ISI) for advanced therapies

Redesigning Important Safety Information (ISI) for advanced therapies

2026 Apr 28 |

Important Safety Information appears throughout branded patient marketing materials. It captures key information that patients with advanced and complex diseases want to know, and supports informed consent for important treatment decisions. Countless hours of co-creation time with patients, caregivers, HCPs, and subject matter experts has helped us think differently about how we can communicate ISI to patients.

read more